IRIS
SARMATI, LOREDANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 52.784
EU - Europa 4.510
AS - Asia 1.511
OC - Oceania 85
SA - Sud America 50
Continente sconosciuto - Info sul continente non disponibili 19
AF - Africa 14
Totale 58.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 52.739
IT - Italia 965
IE - Irlanda 728
DE - Germania 721
UA - Ucraina 703
KR - Corea 667
CN - Cina 657
SE - Svezia 369
GB - Regno Unito 270
FR - Francia 241
FI - Finlandia 168
PL - Polonia 127
AU - Australia 83
BE - Belgio 78
RU - Federazione Russa 66
CA - Canada 39
IN - India 36
HK - Hong Kong 28
JP - Giappone 23
VN - Vietnam 18
BR - Brasile 17
KG - Kirghizistan 16
NL - Olanda 16
ES - Italia 15
EU - Europa 14
CL - Cile 13
PK - Pakistan 12
CH - Svizzera 9
IQ - Iraq 9
CO - Colombia 8
RO - Romania 8
TW - Taiwan 8
SG - Singapore 7
MX - Messico 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AR - Argentina 5
ET - Etiopia 5
IL - Israele 5
PE - Perù 5
SA - Arabia Saudita 5
TR - Turchia 5
AT - Austria 4
GR - Grecia 4
IR - Iran 4
MD - Moldavia 4
BA - Bosnia-Erzegovina 3
CM - Camerun 2
EC - Ecuador 2
EG - Egitto 2
ID - Indonesia 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
DK - Danimarca 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 58.973
Salva come PNG Salva come JPEG
Città #
Woodbridge 15.105
Wilmington 14.823
Houston 11.445
Fairfield 1.848
Chandler 1.414
Ann Arbor 1.400
Ashburn 943
Seattle 765
Cambridge 637
Dublin 631
Jacksonville 598
Medford 457
Rome 422
Dearborn 396
New York 341
Beijing 291
Lawrence 218
San Diego 141
Kraków 122
Menlo Park 98
Milan 87
Zhengzhou 86
Brussels 77
Mülheim 74
Boardman 51
London 46
Palo Alto 44
San Mateo 40
Creede 36
Falls Church 36
Guangzhou 36
Hangzhou 36
Norwalk 34
Engelhard 33
Redwood City 33
Helsinki 32
Sydney 31
Hefei 29
Melbourne 28
Toronto 28
Mountain View 25
Nanjing 25
Shanghai 24
Seoul 23
Verona 23
University Park 22
Canberra 20
Hong Kong 20
Kunming 19
Phoenix 17
Cedarhurst 15
Jinan 14
La Veta 14
Auburn Hills 13
Naples 12
Redmond 12
São Paulo 12
Colorado Springs 11
Council Bluffs 11
Dong Ket 11
Los Angeles 11
Saint Petersburg 11
Washington 11
Wuhan 11
Amsterdam 10
Florence 10
Genoa 10
Indiana 10
Kilburn 10
Nürnberg 10
Roebling 10
Santa Clara 10
Hounslow 9
San Jose 9
Tokyo 9
Bari 8
Citta 8
San Francisco 8
Clearwater 7
Fuzhou 7
Lahore 7
Shenyang 7
St. George 7
Chengdu 6
Detroit 6
Durham 6
Hanoi 6
Monte Vista 6
Nanchang 6
Ottawa 6
Renton 6
Roanoke 6
Tappahannock 6
Turin 6
Bologna 5
Central 5
Città Sant'Angelo 5
Hebei 5
Lappeenranta 5
Lima 5
Totale 53.641
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 489
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 487
Leflunomide-induced DRESS syndrome 473
Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals 468
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis 459
A randomized controlled study for the evaluation of the activity of a triple combination of zidovudine, thymosin-alpha(1) and interferon-alpha in HIV-infected individuals with CD4 counts between 200 and 500 cells/mm(3) 441
Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens 437
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 437
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy 436
Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission 435
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 435
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing 430
Emergence of KPC-producing Klebsiella pneumoniae in Italy 427
Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment 418
A relapsing inflammatory syndrome and active human herpesvirus 8 infection 416
18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. 410
Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma 409
Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals 408
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (< 400 HIV-RNA cp/ml) during different antiretroviral regimens 407
Infection with human herpesvirus type 8 and Kaposi's sarcoma in a central Italian area formerly endemic for malaria 406
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 405
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. 404
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy 403
Candida Albicans Peritoneal Infection in a patient with slerosing Encapsulating Peritonitis under continous peritoneal dialysis. Efficacy of intra-abdominal Amphotericin B and negative pressure after failure of a systemic therapy 403
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis 402
HIV plasma viremia in 22 seropositive subjects [VALUTAZIONE DELLA VIREMIA PLASMATICA DA HIV IN 22 SOGGETTI SIERO-POSITIVI] 401
High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. 400
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors 398
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 397
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations 396
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 396
Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment 394
Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects 393
A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient 392
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART 391
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia 391
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy 391
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 391
Primary human herpesvirus 8 infection in immunocompetent children. 391
Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: An italian multidisciplinary consensus statement 390
Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. 389
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity 388
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon 388
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV 387
Epidemiological record on infectious diseases [NOTIZIARIO EPIDEMIOLOGICO DELLE MALATTIE INFETTIVE] 387
Human herpesvirus 8 and human herpesvirus 2 infections in prison population 386
Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients 382
Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy 381
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 381
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 378
Prevalence trend and correlates of HHV-8 infection in HIV-infected patients 377
Haploidentical, unmanipulated,G-CSF primed bona marrow transplantation for patients with high risk hematological malignancies 377
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation 376
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease 376
KSHV DNA viremia correlates with low CD4+ cell count in Italian males at the time of diagnosis of HIV infection 375
A case of rhabdomiolysis associated with raltegravir use 374
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy 372
Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis 372
Reply to 'Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides', by Barreiro et al. [2] 370
Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. 370
Advances in herpesvirus diagnosis 369
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates 368
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment 368
Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba 366
ellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 363
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy 362
Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. 362
Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy 361
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 361
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 361
HHV-8 infection in African children 360
Serological testing for human herpesvirus 8 360
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 360
Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS [1] 359
Infection with human immunodeficiency virus, herpes simplex virus type 2, and human herpes virus 8 in remote villages of southwestern Papua New Guinea 359
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 359
Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy 358
Stavudine protective function and emergence of lamivudine resistance [4] (multiple letters) 358
ISS-NIA Study Group. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. 357
Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature. 355
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation 355
Human immunodeficiency virus polymorphisms and zidovudine resistance [3] (multiple letters) 355
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment 354
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 353
Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. 352
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. 351
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 350
HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy 347
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 346
Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain. 346
Development of cellulitis caused by Aeromonas hydrophila in allogeneic hematopoietic transplantation: a case report. 345
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 345
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 344
Prevalence and risk factors for herpes simplex virus type 2 infection among adolescents and adults in northern Cameroon 343
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 343
Human immunodeficiency virus polymorphisms and zidovudine resistance 342
Human immunodeficiency virus infection of human bone marrow stromal myoid cells 341
Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. 337
Erysipeloid cutaneous metastasis from bladder carcinoma 333
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review 332
Totale 38.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.471
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.978 0 0 0 0 0 0 0 0 0 0 1.578 1.400
2019/202015.966 1.286 1.407 1.109 1.383 1.423 1.774 1.530 1.343 1.326 1.305 1.012 1.068
2020/20219.162 1.047 991 971 1.214 889 985 1.241 830 210 273 362 149
2021/20222.953 116 230 150 179 125 398 208 158 312 241 174 662
2022/20233.798 337 317 227 531 334 775 280 297 356 35 200 109
2023/20241.484 222 48 173 103 174 368 87 127 41 138 3 0
Totale 59.760